Mezlocillin: Difference between revisions
m Protected "Mezlocillin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
No edit summary |
||
(2 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
{{ | {{Drugbox | ||
| verifiedrevid = 462252118 | |||
| IUPAC_name = (2''S'',5''R'',6''R'')-3,3-dimethyl-6-<nowiki>[[</nowiki>(2''R'')-2-[(3-methylsulfonyl-<br>2-oxo-imidazolidine-1-carbonyl)amino]-2-phenyl-acetyl]<br>amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-<br>carboxylic acid | | IUPAC_name = (2''S'',5''R'',6''R'')-3,3-dimethyl-6-<nowiki>[[</nowiki>(2''R'')-2-[(3-methylsulfonyl-<br>2-oxo-imidazolidine-1-carbonyl)amino]-2-phenyl-acetyl]<br>amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-<br>carboxylic acid | ||
| image = Mezlocillin. | | image = Mezlocillin.png | ||
<!--Clinical data--> | |||
| tradename = | |||
| Drugs.com = {{drugs.com|CONS|mezlocillin}} | |||
| pregnancy_category = B | |||
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 --> | |||
| legal_UK = <!-- GSL / P / POM / CD --> | |||
| legal_US = <!-- OTC / Rx-only --> | |||
| legal_status = | |||
| routes_of_administration = [[Intravenous therapy|Intravenous]], [[Intramuscular injection|intramuscular]] | |||
<!--Pharmacokinetic data--> | |||
| bioavailability = | |||
| protein_bound = 16–59% | |||
| metabolism = [[Liver|Hepatic]] (20–30%) | |||
| elimination_half-life = 1.3–4.4 hours | |||
| excretion = [[Kidney|Renal]] (50%) and biliary | |||
<!--Identifiers--> | |||
| CAS_number_Ref = {{cascite|correct|??}} | |||
| CAS_number = 51481-65-3 | | CAS_number = 51481-65-3 | ||
| ATC_prefix = J01 | | ATC_prefix = J01 | ||
| ATC_suffix = CA10 | | ATC_suffix = CA10 | ||
| ATC_supplemental = | | ATC_supplemental = | ||
| PubChem = 656511 | | PubChem = 656511 | ||
| DrugBank = | | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | ||
| C = 21 | H = 25 | N = 5 | O = 8 | S = 2 | | DrugBank = DB00948 | ||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | |||
| ChemSpiderID = 570894 | |||
| UNII_Ref = {{fdacite|correct|FDA}} | |||
| UNII = OH2O403D1G | |||
| KEGG_Ref = {{keggcite|correct|kegg}} | |||
| KEGG = D05021 | |||
| ChEBI_Ref = {{ebicite|correct|EBI}} | |||
| ChEBI = 6919 | |||
| ChEMBL_Ref = {{ebicite|correct|EBI}} | |||
| ChEMBL = 1731 | |||
<!--Chemical data--> | |||
| C=21 | H=25 | N=5 | O=8 | S=2 | |||
| molecular_weight = 539.584 g/mol | | molecular_weight = 539.584 g/mol | ||
| | | smiles = O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)[C@@H](c1ccccc1)NC(=O)N2C(=O)N(S(=O)(=O)C)CC2)[C@H]4SC3(C)C | ||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} | |||
| StdInChI = 1S/C21H25N5O8S2/c1-21(2)14(18(29)30)26-16(28)13(17(26)35-21)22-15(27)12(11-7-5-4-6-8-11)23-19(31)24-9-10-25(20(24)32)36(3,33)34/h4-8,12-14,17H,9-10H2,1-3H3,(H,22,27)(H,23,31)(H,29,30)/t12-,13-,14+,17-/m1/s1 | |||
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | |||
| StdInChIKey = YPBATNHYBCGSSN-VWPFQQQWSA-N | |||
| | |||
| | |||
| | |||
| | |||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | {{SI}} | ||
{{ | {{CMG}} | ||
'''Mezlocillin''' is a broad-spectrum [[penicillin]] [[antibiotic]]. It is active against both [[Gram-negative]] and some [[Gram-positive]] [[bacteria]]. | ==Overview== | ||
'''Mezlocillin''' is a broad-spectrum [[penicillin]] [[antibiotic]]. It is active against both [[Gram-negative]] and some [[Gram-positive]] [[bacteria]]. Unlike most other extended spectrum penicillins, it is excreted by the liver, therefore it is useful for biliary tract infections, such as ascending colangitis. | |||
==Mechanism of action== | ==Mechanism of action== | ||
Line 43: | Line 74: | ||
*''[[Proteus mirabilis]]'' | *''[[Proteus mirabilis]]'' | ||
*''[[Proteus vulgaris]]'' | *''[[Proteus vulgaris]]'' | ||
*''[[Pseudomonas]]'' spp., including ''[[Pseudomonas aeruginosa|P. aeruginosa]]'' | *''[[Pseudomonas]]'' spp., including ''[[Pseudomonas aeruginosa|P. aeruginosa]]'' | ||
*''[[Serratia marcescens]]'' | *''[[Serratia marcescens]]'' | ||
Line 49: | Line 79: | ||
===Gram-positive=== | ===Gram-positive=== | ||
*''[[Enterococcus faecalis]]'' | *''[[Enterococcus faecalis]]'' | ||
*''[[ | *''[[Peptostreptococcus]]'' spp.'' | ||
==External links== | ==External links== | ||
Line 56: | Line 85: | ||
* {{GPnotebook|-288358398}} | * {{GPnotebook|-288358398}} | ||
* [http://www.wheelessonline.com/ortho/mezlocillin_mezlin Duke] | * [http://www.wheelessonline.com/ortho/mezlocillin_mezlin Duke] | ||
* {{cite journal | author = Kristof R, Clusmann H, Koehler W, Fink K, Schramm J | title = Treatment of accidental high dose intraventricular mezlocillin application by cerebrospinal fluid exchange. | journal = J Neurol Neurosurg Psychiatry | volume = 64 | issue = 3 | pages = | * {{cite journal | author = Kristof R, Clusmann H, Koehler W, Fink K, Schramm J | title = Treatment of accidental high dose intraventricular mezlocillin application by cerebrospinal fluid exchange. | journal = J Neurol Neurosurg Psychiatry | volume = 64 | issue = 3 | pages = 379–81 | year = 1998 | pmid = 9527154 | doi = 10.1136/jnnp.64.3.379 | pmc = 2170014}} | ||
* {{cite journal | author = McCormick P, Greenslade L, Kibbler C, Chin J, Burroughs A, McIntyre N | title = A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients. | journal = Hepatology | volume = 25 | issue = 4 | pages = | * {{cite journal | author = McCormick P, Greenslade L, Kibbler C, Chin J, Burroughs A, McIntyre N | title = A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients. | journal = Hepatology | volume = 25 | issue = 4 | pages = 833–6 | year = 1997 | pmid = 9096584 | doi = 10.1002/hep.510250408}} | ||
* {{cite journal | author = Rohde B, Werner U, Hickstein H, Ehmcke H, Drewelow B | title = Pharmacokinetics of mezlocillin and sulbactam under continuous veno-venous hemodialysis (CVVHD) in intensive care patients with acute renal failure. | journal = Eur J Clin Pharmacol | volume = 53 | issue = 2 | pages = | * {{cite journal | author = Rohde B, Werner U, Hickstein H, Ehmcke H, Drewelow B | title = Pharmacokinetics of mezlocillin and sulbactam under continuous veno-venous hemodialysis (CVVHD) in intensive care patients with acute renal failure. | journal = Eur J Clin Pharmacol | volume = 53 | issue = 2 | pages = 111–5 | year = 1997 | pmid = 9403281 | doi = 10.1007/s002280050347}} | ||
{{PenicillinAntiBiotics}} | {{PenicillinAntiBiotics}} | ||
[[Category:Beta-lactam antibiotics]] | [[Category:Beta-lactam antibiotics]] | ||
[[Category:Drug]] | |||
Latest revision as of 14:41, 13 April 2015
Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Pregnancy category |
|
Routes of administration | Intravenous, intramuscular |
ATC code | |
Pharmacokinetic data | |
Protein binding | 16–59% |
Metabolism | Hepatic (20–30%) |
Elimination half-life | 1.3–4.4 hours |
Excretion | Renal (50%) and biliary |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C21H25N5O8S2 |
Molar mass | 539.584 g/mol |
3D model (JSmol) | |
| |
| |
(verify) |
WikiDoc Resources for Mezlocillin |
Articles |
---|
Most recent articles on Mezlocillin Most cited articles on Mezlocillin |
Media |
Powerpoint slides on Mezlocillin |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Mezlocillin at Clinical Trials.gov Clinical Trials on Mezlocillin at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Mezlocillin
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Mezlocillin Discussion groups on Mezlocillin Patient Handouts on Mezlocillin Directions to Hospitals Treating Mezlocillin Risk calculators and risk factors for Mezlocillin
|
Healthcare Provider Resources |
Causes & Risk Factors for Mezlocillin |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Mezlocillin is a broad-spectrum penicillin antibiotic. It is active against both Gram-negative and some Gram-positive bacteria. Unlike most other extended spectrum penicillins, it is excreted by the liver, therefore it is useful for biliary tract infections, such as ascending colangitis.
Mechanism of action
Like all other beta-lactam antibiotics, mezlocillin inhibits the third and last stage of bacterial cell wall synthesis by binding to penicillin binding proteins. This ultimately leads to cell lysis.
Susceptible organisms
Gram-negative
- Bacteroides spp., including B. fragilis
- Enterobacter spp.
- Escherichia coli
- Haemophilus influenzae
- Klebsiella species
- Morganella morganii
- Neisseria gonorrhoeae
- Proteus mirabilis
- Proteus vulgaris
- Pseudomonas spp., including P. aeruginosa
- Serratia marcescens
Gram-positive
External links
- Template:DiseasesDB
- Template:GPnotebook
- Duke
- Kristof R, Clusmann H, Koehler W, Fink K, Schramm J (1998). "Treatment of accidental high dose intraventricular mezlocillin application by cerebrospinal fluid exchange". J Neurol Neurosurg Psychiatry. 64 (3): 379–81. doi:10.1136/jnnp.64.3.379. PMC 2170014. PMID 9527154.
- McCormick P, Greenslade L, Kibbler C, Chin J, Burroughs A, McIntyre N (1997). "A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients". Hepatology. 25 (4): 833–6. doi:10.1002/hep.510250408. PMID 9096584.
- Rohde B, Werner U, Hickstein H, Ehmcke H, Drewelow B (1997). "Pharmacokinetics of mezlocillin and sulbactam under continuous veno-venous hemodialysis (CVVHD) in intensive care patients with acute renal failure". Eur J Clin Pharmacol. 53 (2): 111–5. doi:10.1007/s002280050347. PMID 9403281.